Adcock Ingram maintains upward earnings trajectory in FY17

The 2017 financial results of “re-engineered” pharmaceuticals giant Adcock Ingram show continued recovery and positive performance three years after the group embarked on a significant restructure to turn around its fortunes. Adcock’s “satisfying trading performance and exceptional increase in trading profits” for the year ended June 30, were characterised by double-digit increases in earnings despite the economic downturn and consumer spending pressure.